A. Zinkina-Orikhan

发表

[Efficacy, tolerability and safety of the treatment with teberif: the results of a 2-year randomized clinical trial of treatment naïve patients with remitting multiple sclerosis, who have not received DMT, after switching from other interferon β-1a].

M. Zakharova, A. Boyko, S. Prokopenko, 2019, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety].

O. Boyko, A. Boyko, P. Yakovlev, 2019, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

A Comparative Placebo-Controlled Clinical Trial of the Efficacy and Safety of Interferon β-1a Formulations for S.C. Administration in Patients with Remitting Multiple Sclerosis: First-Year Results

M. Zakharova, S. Prokopenko, F. Khabirov, 2018, Neuroscience and Behavioral Physiology.

[A comparative placebo-controlled clinical study on the efficacy and safety of interferon beta-1a for subcutaneous injections in patients with remitting multiple sclerosis: results of the first year of observations].

M. Zakharova, A. Boyko, S. Prokopenko, 2017, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study

V. Mazurov, O. Moiseeva, M. Gilyarov, 2021, Inflammation research : official journal of the European Histamine Research Society ... [et al.].

Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial

L. Puig, A. Samtsov, Ivan V. Kuryshev, 2021, Dermatology and Therapy.

Efficacy and safety profile of 2-year netakimab treatment in patients with moderate-to-severe plaque psoriasis in terms of the randomized double-blind placebo-controlled BCD-085-7/PLANETA clinical trial

A. Samtsov, M. Kokhan, V. R. Khairutdinov, 2022, Vestnik dermatologii i venerologii.

Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study

V. Mazurov, A. Lila, A. Samtsov, 2022, Rheumatology Science and Practice.

[The efficacy and safety of eculizumab biosimilar in patients with paroxysmal nocturnal hemoglobinuria. Results of a phase III randomized open-label comparative clinical trial].

V. Mazurov, T. Konstantinova, M. Morozova, 2021, Terapevticheskii arkhiv.

[The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis].

A. Boyko, K. Bakhtiyarova, N. Malkova, 2019, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)

S. Fogt, A. Snegovoy, A. Zinkina-Orikhan, 2023, Safety and Risk of Pharmacotherapy.

[Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results].

S. Sivertseva, M. Zakharova, O. Boyko, 2023, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova.

[Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].

O. Boyko, N. Totolyan, F. Khabirov, 2022, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 56-week results of phase III randomized double-blind placebo-controlled trial SOLAR

V. Mazurov, A. Lila, M. Korolev, 2023, Rheumatology Science and Practice.

Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study

D. Stroyakovskiy, S. Protsenko, S. Odintsova, 2023, Journal of Modern Oncology.

A Comparative Placebo-Controlled Clinical Trial of the Efficacy and Safety of Interferon β-1a Formulations for S.C. Administration in Patients with Remitting Multiple Sclerosis: First-Year Results

M. Zakharova, S. Prokopenko, F. Khabirov, 2018, Neuroscience and Behavioral Physiology.

Levilimab clinical efficacy for interleukin-6 receptor inhibition in COVID-19 and its potential for treating cytokine release syndrome of other aetiologies

E. Smolyarchuk, M. Morozova, N. Lomakin, 2022, Biological Products. Prevention, Diagnosis, Treatment.

Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

S. Lapshina, I. Gordeev, T. Dubinina, 2020, Modern Rheumatology Journal.